Cytotherapy

Aims and Scope 

Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. In addition to Short Reports and Full-Length Articles, the journal also accepts Editorials on emerging trends and potential controversies in the field, and Review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.

Cytotherapy considers manuscripts exploring the following topics:

  • Gene, cell (includes stem cells and iPSCs) and EV-based therapies
  • Regulatory frameworks and policy issues in CGT
  • Novel and innovative results from basic, translational, and clinical studies in CGT
  • Important advances in cell/gene-based product manufacturing,
    commercialization and patient access
  • Clinical studies evaluating the safety and efficacy of cell and gene therapies

Cytotherapy does not publish manuscripts on the following topics:

  • Case studies unless they are of unusual significance to the field.
  • Basic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiology
  • Studies describing signaling pathways implicated in cancer

Mission Statement

To be the premier cell and gene therapy translation journal.


Submit a Manuscript

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt, whether the manuscript is accepted, requires revision, or is rejected. All manuscripts will be published within 5 months from the date of acceptance.

Submit Now


Journal Leadership

Editor-in-Chief

Edwin M. Horwitz
MD, PhD
Emory University School of Medicine
United States

Managing Editor

Kenneth W. Witwer
PhD
Johns Hopkins University
United States

Commissioning Editor

Patrick J. Hanley
PhD
Children's National Hospital
United States


Associate Editors

Shin Kawamata
MD, PhD
Cyto-Facto
Japan

Sai Kiang Lim
PhD
Paracrine
Therapeutics Pte Ltd
Singapore

George Muschler
PhD
Cleveland Clinic
United States

Anna Pasetto
PhD
Oslo University
Hospital
Norway

Susan Prockop
MD
Boston Children's
Hospital
United States

Qasim Rafiq
MEng, PhD
University College
London
United Kingdom

Sowmya Viswanathan
PhD
University Health Network
Canada


Assistant Editor

Rachel A. Burga
PhD
Obsidian Therapeutics
United States


Cytotherapy logo

5-Year Impact Factor

5.0

Connect 

Join us on:

LinkedIn | Twitter

Access Journal

For questions and issues about accessing Cytotherapy, contact Sam Baker: sam@isctglobal.org.

Paul Cumine
Interim Publisher, Cytotherapy

Cytotherapy logo

Editorial Board Members